Table 1.
Baseline demographic and clinical patients' characteristics.
| Patient n = 38 | ||
|---|---|---|
| Median age, years (range) | < 70, n (%) | 61 (42–79) |
| ≥70, n (%) | 17 (44.7%) | |
| 21 (55.3%) | ||
| Sex | male n (%) | 22 (57.9%) |
| female n (%) | 16 (42.1%) | |
| PS Karnofsky, n (%) | 100–90% | 5 (13.1%) |
| 80–70% | 27 (71.8%) | |
| ≥60% | 6 (15.8%) | |
| Comorbidities, n (%) | 0 | 4 (10.5%) |
| 1 | 6 (15.7%) | |
| 2 | 17 (44.7%) | |
| ≥3 | 11 (28.9%) | |
| Hypertension (%) | yes | 21 (55.3%) |
| no | 17 (44.7%) | |
| Metastatic disease at diagnosis (%) | Yes | 19 (50%) |
| No | 19 (50%) | |
| MSKCC/Motzer Score*, n (%) | Favorable | 5 (13.1%) |
| Intermediate | 24 (63.1%) | |
| Poor | 4 (12.5%) | |
| Unknown | 0 | |
| Prior nephrectomy, n (%) | 23 (60.5%) | |
| Time form diagnosis to treatment, months (range) | 13 (1–96) | |
| Hystology, n (%) | Clear cell carcinoma | 32 (84.2%) |
| Type I papillary | 1 (2.6%) | |
| Type II papillary | 2 (5.3%) | |
| Cromophobe | 1 (2.6%) | |
| Sarcomatoid variant | 2 (5.3%) | |
| Number of metastatic sites, n (%) | < 6 | 23 (60.5%) |
| ≥6 | 15 (39.4%) | |
| Most common metastatic sites, n (%) | Lung | 21 (55.3%) |
| Bone | 18 (47.4%) | |
| Lymph nodes | 16 (42.1%) | |
| Liver | 4 (10.5%) | |
| Other | 10 (26.3%) |
n, number of patients.
*
Memorial Sloan-Kettering Cancer Center.